NovoEight® (turoctocog alfa, recombinant factor VIII) ) is launched. NovoEight® is based on advanced protein and purification technology, and is a new choice in FVIII treatment for people with haemophilia A.
Tresiba®, (insulin degludec) is launched. Tresiba is a new-generation basal insulin analogue with ultra-long duration of action beyond 42 hours.
Tretten® (rFXIII, catridecacog)(also known as NovoThirteen®), a recombinant product for factor XIII-A subunit congenital deficiency is launched.
Vagifem® 10 mcg is launched in the US and Europe. The medication provides the lowest dose of vaginal oestrogen commercially available for women with vaginal atrophy.
Novo Nordisk launches NovoPen Echo®, a new insulin pen developed especially for children. Initially launched in Denmark, the pen includes a memory function and half-unit dosing increments.
Victoza® – human Glucagon-Like Peptide-1 (GLP-1) analogue for once-daily treatment of adults with type 2 diabetes – is launched in Europe.
Activella® 0.5 mg/0.1 mg is launched in the US – the first ultra-low-dose oral HRT for women with menopausal symptoms.
In Montes Claros, Brazil, Novo Nordisk inaugurates its largest insulin production facility outside of Denmark.
Novo Nordisk signs an agreement with WWF that commits the company to reduce its carbon emissions by 10% by 2014 compared with 2004. Novo Nordisk is the 10th company in the world to join the WWF Climate Savers initiative.
The Novo Nordisk Haemophilia Foundation is set up in response to the significant need to improve haemophilia treatment in the developing world, underlining the company’s social responsibility within haemophilia care.
Levemir® is launched – a long-acting modern insulin.
Novo Nordisk’s Articles of Association are amended to specify that the company will “strive to conduct its activities in a financially, environmentally and socially responsible way”.
Norditropin NordiFlex® is launched – the world’s first prefilled growth hormone pen.
Novo Nordisk signs the United Nations Global Compact, a platform for promoting good corporate principles and learning experiences in the areas of human rights, labour, environment and anti-corruption.
NovoMix® 30 is introduced – a dual-release modern insulin.
InnoLet® is launched – the first insulin delivery system specially designed to suit the needs of insulin users with poor eyesight and reduced dexterity.
Novo Nordisk establishes the World Diabetes
Foundation with the purpose of improving diabetes care in developing countries.
NovoRapid® FlexPen® is marketed. FlexPen® is a new prefilled pen, designed for easy and discreet use.
Novo Nordisk is split into three separate companies operating under the umbrella of the Novo Group:
Novo Nordisk A/S, Novozymes A/S and Novo A/S.
Novo Nordisk publishes its first social report.
NovoRapid® (NovoLog® in the US) – the company’s first modern insulin, a rapid-acting insulin analogue – is marketed. Modern insulins are designed to better mimic the normal insulin response to changes in blood sugar levels.
Norditropin® SimpleXx® is launched – the world’s first liquid growth hormone in a dedicated pen system.
Activelle® (Activella® in the US) is introduced – the first low-dose continuous combined oral HRT for postmenopausal women.
NovoNorm® (Prandin® in the US) – a new oral treatment for type 2 diabetes – is launched in the US and a number of European countries.
NovoSeven® is launched – for the treatment of haemophilia patients with inhibitor reaction.
Novo Nordisk is the first company in Denmark – and one of the first in the world – to publish an environmental report.
The Steno Memorial Hospital and Hvidøre Hospital merge to form the Steno Diabetes Center.
Novo Nordisk joins the environmental charter of the International Chamber of Commerce (ICC).
Nordisk Insulinlaboratorium, the Nordisk Insulin Foundation and the Novo Foundation merge to become the Novo Nordisk Foundation. The objects are to provide a stable basis for the Novo Group companies’ operations and to support scientific causes. Novo Industri A/S and Nordisk Gentofte A/S merge to become Novo Nordisk A/S – the world’s leading producer of insulin. NovoLet® is marketed – the world’s first prefilled insulin syringe.
Novo markets Vagifem® – the first vaginal tablet for atrophic vaginitis.
Nordisk markets Norditropin® genetically engineered human growth hormone.
Novo starts production of human insulin with the help of genetically engineered yeast cells.
NovoPen® is launched – an injection system similar in appearance to a fountain pen, with replaceable insulin cartridges.
Human Monocomponent insulin is launched – the world’s first insulin preparation identical to human insulin. It is extracted from the pancreases of pigs and converted to human insulin.
Novo becomes the first company in Scandinavia to be quoted on the New York Stock Exchange.
Novo’s B shares are quoted on the Copenhagen Stock Exchange.
Novo introduces Monocomponent (MC) insulin – the purest insulin available.
Nordisk markets Nanormon® growth hormone for the treatment of growth hormone insufficiency. The growth hormone is extracted from human pituitary glands.
Novo launches Lente® – a long-acting insulin–zinc suspension.
Novo establishes the Novo Foundation with the object of supporting scientific, social and humanitarian causes and to provide the best possible protection for the company.
Penicillin Novo is launched – Novo’s first product to be manufactured through fermentation.
Nordisk develops isophane insulin (NPH), a neutral insulin with prolonged action.
Novo founds Hvidøre Diabetes Sanatorium.
Nordisk founds the Steno Memorial Hospital.
Nordisk establishes the Nordisk Insulin Foundation with the object of supporting physiological and
endocrinological research and people with diabetes in Scandinavia.
Novo Terapeutisk Laboratorium founded.
Nordisk Insulinlaboratorium founded.